The director of the Mario Negri Institute for Pharmacological Research in Milan says that the patients of today are completely different from those of three or four weeks ago

By: Web Writing

Italy.- Several months after the sick by coronavirus in the world, it seems that we are currently facing a very different from which it came to alter our fast-paced lifestyle.

This was considered by Professor Giuseppe Remuzzi, director of the Mario Negri Institute for Pharmacological Research in Milan.

“The patients are now completely different from those of three or four weeks ago, intensive care and hospitalizations continue to decrease in hospitals,” said the professor.


Being cautious that a second wave of the Covid-19 pandemic may arise, Professor Giuseppe Remuzzi dares to predict that perhaps the disappearance of the coronavirus it arrives before the vaccine, which may still take a few months.

“There will be a vaccine, but probably when it arrives, I hope, if things continue as they are now, the virus will be gone. But the vaccine will be useful for next time or for other viruses,” Remuzzi said.


Guido Silvestri, a prestigious Italian immunologist and virologist, also made statements that the coronavirus no longer as aggressive as when the first ones started sick.

“The virus could experience a significant reduction in its ability to cause disease, as several colleagues seem convinced that this is already happening.”



Guido Silvestri also runs one of the most advanced research laboratories in Microbiology and Immunology, and today he writes hopeful news on the Medical Facts website:

“I have long argued that the most promising therapies against Covid-19 are those based on specific antivirals (Remdesivir, EIDD 2801), monoclonal antibodies and / or convalescent plasma, and medications capable of fighting the ‘cytokine storm’. For this reason , I am happy that today the first controlled clinical trial has officially started evaluating the combination of an antiviral, Remdesivir, with an immunomodulator, Baricitinib (the control group will receive Remdesivir alone.) The trial is called Adaptive COVID-19 Treatment Trial 2 (ACTT2) and will involve more than 1,000 patients in 100 hospitals in the United States and abroad, “Silvestri announced.


However, Massimo Galli, head of the infectious diseases department of the Sacco hospital in Milan does not share Professor Negri’s idea, confirms that there are sick less serious but not because the coronavirus have had a change in motivation.

For his part, he is more cautious and offers an explanation for this sick less serious.

“The fact that there are less serious people in hospitals may be motivated because we are at the tail end of an epidemic that has seen the most fragile people present the most serious forms in the past two months, but that does not mean that there has been attenuated the virus, “explained Massimo Galli.